Drug intelligence / Profile preview

Calcipro

Development stage: Unknown
Lead developer: lege artis Pharma
Modality: Small Molecules
Administration: Topical

Overview

Calcipro is a dental medical device consisting of a radiopaque calcium hydroxide powder, developed and manufactured by the German company lege artis Pharma. It is specifically designed for use in endodontics as an intracanal medicament during root canal treatments. The powder is typically mixed with a sterile liquid to create a paste of a desired consistency, which is then applied topically within the dental root canal system. Its therapeutic action is primarily mediated by the high alkalinity of calcium hydroxide (pH approximately 12.5), which exerts potent antimicrobial effects, aids in the dissolution of necrotic tissue remnants, and stimulates the formation of hard tissue barriers, such as in apexification or the treatment of root resorptions.

Brand names: Calcipro
Other names: calcium hydroxide powder

Beyond the preview

Go deeper on Calcipro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcipro.

Explore the full profile